Dr. Noon CVD

A retinal-based AI diagnostic solution that autonomously assesses the future risk of cardiovascular disease (CVD).

Check your cardiovascular disease risk with retina image

*DrNoon is an approved product name of Dr. Noon CVD and Dr. Noon Fundus in some territories

Features

The first retinal-based AI solution to assess your cardiovascular risk

Dr. Noon expands solutions to detect heart disease. You can predict your personalized CVD risk without a blood sampling or radiation

Effective CVD risk stratification and triage tool

Our deep-learning algorithm can estimate your Cardiovascular Disease risk as an adjunct to the formal risk assessment tools such as heart CT scan

Meeting prognostic performance of heart CT in projecting CVD events

Dr. Noon CVD can autonomously predict your future CVD risk while meeting the heart CT performance

Meet Dr. Noon CVD

*DrNoon is an approved product name of Dr. Noon CVD and Dr. Noon Fundus in some territories

Dr. Noon CVD vs. Traditional clinical measures 

The graphs demonstrate the performance of Reti-CVD, an AI-based tool using retinal images for cardiovascular disease (CVD) risk prediction, compared to traditional clinical measures such as Coronary Artery Calcium (CAC) score, Carotid Intima-Media Thickness (CIMT), and Brachial-Ankle Pulse Wave Velocity (baPWV). Reti-CVD effectively stratifies patients into low, moderate, and high-risk groups, with a clear gradient of increasing cumulative CVD event rates over five years, outperforming the other measures in predictive accuracy. While CAC, CIMT, and baPWV also show associations with CVD risk, their stratification is less distinct. These results highlight Reti-CVD’s potential as a non-invasive, scalable, and highly effective AI-driven tool for early and personalized CVD risk assessment, offering significant advantages for clinical decision-making and patient care.

[Figure 5.3.3.2 Kaplan–Meier estimates for cumulative incidence of cardiovascular events in the CMERC-HI cohort. Cardiovascular disease event according to Reti-CVD-three risk groups (A), coronary artery calcium (CAC)-based 3 risk groups (B), carotid intima-media thickness (CIMT)-based 2 risk groups (C), and brachial-ankle pulse wave velocity (baPWV)-based 2 risk groups (D). Cardiovascular disease events included incident heart failure, stroke, myocardial infarction, and cardiovascular mortality. CMERC-HI, Cardiovascular and Metabolic Disease Etiology Research Center-High Risk. Reti-CVD shows distinct CVD risk stratification based on 3 groups (Figure A). CAC-three groups, and CIMT- and baPWV-two risk groups also show distinct CVD risk stratifications as shown in Figure B-D]

Benefits

Safe

Skip any blood tests or radiation exposure while meeting the CT performance

Affordable

Save costs through early detection of stroke and heart disease prevention

Accessible

Provide patients with comprehensive cardiovascular risk management in a primary care setting

Dr. Noon CVD vs. Heart CT, Carotid Ultrasound

Dr. Noon CVD

Measured by Retina-based Coronary Artery Calcium Score

  • No radiation risk or blood test
  • Similar to retina photo cost
  • Available in primary care setting
  • From test to result within a minute
  • Comparable performance to heart CT scan in risk assessment

Heart CT Scan

Measured by Heart CT-based Coronary Artery Calcium Score

  • Exposure to high-dose radiation
  • Not available in primary care settings
  • Relatively high cost
  • Test is taken by operation staff, read by radiologists, and delivered to patients by cardiologists, taking few weeks from test to result

Carotid Ultrasound

Measured by Carotid Intima-Media Thickness

  • Test can be taken only by physicians for over 10 minutes
  • Relatively low accuracy compared to coronary artery calcium score in predicting cardiovascular disease risk
  • Higher cost than taking a retina photo 

How Dr. Noon CVD works

Eye Scan

Take 1 retinal photograph per eye using a fundus camera by optometrists or technicians

Upload

Submit images to the cloud for analysis and type patient information

Analysis

Automatically analyze for signs of CVD risk within a minute

Report

Generate personalized health screening results and download the report

Referral

Refer to specialists for further follow-up or suggest lifestyle changes and regular check-ups

7

Get your result immediately.

Approval of Medical device & Commercial use

Approved in 8 territories, Reimbursed in Korea

Mediwhale is the only company that obtained approval for cardiovascular disease risk assessment using retinal images as a biomarker. Dr. Noon CVD has approvals for medical devices in the EU and Asia and is under FDA clearance in the US.

Dr. Noon CVD has been selected for the Postponement of New Health Technology Assessment (nHTA) in Korea. It has become the pioneering medical AI technology that physicians can use for early detection of CVD. Patients now have a formal process to get reimbursement for Dr. Noon CVD. 

DrNoon is an approved product name of Dr. Noon CVD and Dr. Noon Fundus in some territories.

Publication

Deep-learning-based cardiovascular risk stratification using coronary artery calcium scores predicted from retinal photographs

The Lancet Digital Health

Coronary Artery Calcium (CAC) score is a clinically validated marker of cardiovascular disease risk. 

Publication

Pivotal trial of a deep-learning-based retinal biomarker (Reti-CVD) in the prediction of cardiovascular disease: data from CMERC-HI

JAMIA

The potential of using retinal images as a biomarker of cardiovascular disease (CVD) risk has gained significant attention, but regulatory approval of such artificial intelligence (AI) algorithms is lacking.